Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A

Plain-language summary

This study examines the genetic factors that influence the response to Desmopressin (DDAVP) treatment in female carriers of hemophilia A. It included women diagnosed as hemophilia A carriers based on F8 gene analysis who had received Desmopressin in the last 10 years. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Groupe Maladies hémorragiques de Bretagne

Intervention

Desmopressin

Start date

1/1/2022

Estimated completion

4/1/2023

Countries

France

Related genes

Locations

• Bordeaux, France
• Brest, France
• Bron, France
• Dijon, France
• Le Kremlin-Bicêtre, France
• Lille, France
• Marseille, France
• Montpellier, France
• Nancy, France
• Nantes, France
• Rennes, France
• Saint-Etienne, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Females at any ages with a formal diagnosis of HA carriers based on the F8 genetics,
* Patients having received DDAVP during the last 10 years that was associated with dosages of FVIII before and just after DDAVP,
* Factor VIII levels measurements realized at least 2 times during the therapeutic test, just before the DDAVP infusion and 30 or 60 minutes after.

Exclusion Criteria:

* Patients with an anti-factor VIII inhibitor,
* Refusal to participate in the study,
* Unable to understand the study's French letter of non-opposition and information